Republic Technologies beauftragt Fireblocks zur Stärkung des institutionellen Risikomanagements
Vancouver, British Columbia--(Newsfile Corp. - Freitag, 19. September 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (das "Unternehmen" oder "Republic") gibt heute eine strategische Zusammenarbeit mit Fireblocks bekannt - der Enterprise-Plattform, der weltweit über 2.200 Organisationen für die sichere Verwahrung und den Betrieb digitaler Vermögenswerte vertrauen. Die Partnerschaft verschafft Republic Zugang zu modernsten Verwahrungs-, Governance- und R
Technology, Pharmaceuticals, Health
2025-09-19 3:14 AM EDT | Republic Technologies Inc.
Republic Technologies Engages Fireblocks to Bolster Institutional-Grade Risk Management
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") today announced a strategic engagement with Fireblocks, the enterprise platform trusted by over 2,200 organizations worldwide for secure digital asset custody and operations. The partnership will provide Republic with advanced custody, governance, and risk controls to safeguard its ETH-denominated treasury and
Technology, Pharmaceuticals, Health
2025-09-19 3:13 AM EDT | Republic Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced that Phio Pharmaceuticals is a presenting company at the Life Sciences Future Conference to be held September 25 - 26, 2025. Mr. Robert Bitterman, President and CEO of Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-18 7:45 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that
Biotechnology, Pharmaceuticals, Health
2025-09-17 7:52 AM EDT | Hemostemix Inc.
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that Croom Lawren
Biotechnology, Pharmaceuticals, Health
2025-09-16 2:52 PM EDT | Hemostemix Inc.
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA to its Board of Directors, effective immediately. Dr. Phinney recently joined Defence as a Strategy and Business Advisor, working closely with leadership to refine the Co
Biotechnology, Pharmaceuticals, Health
2025-09-16 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of $2,000,000 (the "Offering"). Each Unit consisted of (i) on
Biotechnology, Pharmaceuticals, Health
2025-09-15 4:30 PM EDT | Defence Therapeutics Inc.
Nextleaf Provides Strategic Update: Canada's First 200-Pack Cannabis Softgels, and Opening of Distribution Facility
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor announces the launch of Canada's first 200-pack cannabis softgels under its house brand Glacial Gold™, and the opening of a new distribution facility. Together, these developments strengthen Nextleaf's position in existing markets and enh
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-09-11 9:00 AM EDT | Nextleaf Solutions Ltd.
Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM - the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms - today announced that the Company will host an Investor Webinar on Tuesday, September 16, 2025 at 1:30 p.m. Pacific time, 430 p.m. Eastern Standard Time. During the webinar, Unbuzzd C
2025-09-11 7:00 AM EDT | Unbuzzd Wellness Inc.
Republic Technologies geht Partnerschaft mit FalconX zur Unterstützung von Ethereum-Validator-Operationen ein
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 11. September 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (das "Unternehmen" oder "Republic") freut sich, eine strategische Partnerschaft mit FalconX, einem führenden Prime-Broker für digitale Vermögenswerte, bekannt zu geben. Ziel der Zusammenarbeit ist es, ETH-Liquidität und Ausführungsunterstützung für die Validator-Infrastruktur von Republic berei
Technology, Pharmaceuticals, Health
2025-09-11 2:02 AM EDT | Republic Technologies Inc.
Republic Technologies Partners with FalconX to Support Ethereum Validator Operations
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce a strategic partnership with FalconX, a notable digital asset prime brokerage, to provide ETH liquidity and execution support for Republic's validator infrastructure, which underpins its attestation services. Republic is currently building out its attestation platform, which will al
Technology, Pharmaceuticals, Health
2025-09-11 2:00 AM EDT | Republic Technologies Inc.
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, a
Biotechnology, Pharmaceuticals, Health
2025-09-10 4:37 PM EDT | Hemostemix Inc.
BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
Rehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability
Biotechnology, Pharmaceuticals, Health
2025-09-10 7:00 AM EDT | BioHarvest Sciences Inc.
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces a non broke
Biotechnology, Pharmaceuticals, Health
2025-09-09 8:47 AM EDT | Hemostemix Inc.
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces the launch
Biotechnology, Pharmaceuticals, Health
2025-09-09 6:13 AM EDT | Hemostemix Inc.
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common share
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-08 7:00 AM EDT | Optimi Health Corp.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 unit
Biotechnology, Pharmaceuticals, Health
2025-09-05 4:58 PM EDT | PreveCeutical Medical Inc.
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMe
Biotechnology, Pharmaceuticals
2025-09-05 1:33 PM EDT | InMed Pharmaceuticals
Republic Technologies Announces Adoption of Advance Notice Policy
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (the "Company" or "Republic") is pleased to announce that the board of directors (the "Board") of the Company approved an advance notice policy (the "Advance Notice Policy") on September 4, 2025 with effect as of such date. The Advance Notice Policy includes, among other things, a provision that requires advance notice be given to the
Technology, Pharmaceuticals, Health
2025-09-04 9:42 PM EDT | Republic Technologies Inc.
Genix Pharmaceuticals Closes Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces that it has closed its previously announced non-brokered private placement raising gross proceeds of $100,000. The Company has issued 2,000,000 units (each a "Unit") at a price of $0.10 per Unit. Each Unit consists of one common share of the Company (a "Share") and one transferable common share purchase warrant (a "Warra
Biotechnology, Pharmaceuticals, Health
2025-09-04 4:15 PM EDT | Genix Pharmaceuticals Corp.